MIS Trends 2014: Improving Visualization

Innovation is driving healthy growth in the multibillion-dollar market for minimally invasive surgical products as manufacturers develop new laparoscopic visualization systems and advanced surgical tools with robotic-like features designed to enable more complex procedures to be performed via a minimally invasive approach.

Manufacturers of minimally invasive surgical (MIS) products are developing new laparoscopic visualization systems and advanced surgical tools designed to offer some of the benefits of robotic surgery without the challenges posed by current robotic platforms. These companies are counting on such hybrid solutions to provide a technological and economic middle ground between traditional laparoscopy and robotic surgery and enable more complex procedures to be performed via a minimally invasive approach. Advances in imaging, such as three-dimensional (3D) high-definition (HD) laparoscopy systems (3D HD), fluorescence imaging, and image guidance, along with new handheld tools and energy devices designed to enhance dexterity, maneuverability, rotation, precision, and ergonomics will continue to drive growth in the multibillion-dollar MIS products market. Manufacturers are also driving growth by targeting underpenetrated and emerging markets, particularly in Asia and Latin America, and by focusing education, sales, and product development efforts on underserved clinical areas with good potential for increasing MIS adoption in gynecologic, thoracic, hepatobiliary, pancreatic, colorectal, oncologic, and bariatric surgery. (SeeAlso see "Trends In MIS, Part I: Pushing Surgical Boundaries" - Medtech Insight, 25 May, 2012..)

In part one of this two-part series, Medtech Insight covers the latest advances in laparoscopic visualization, and highlights the trends that are driving growth in the market for endoscopic imaging technologies. Total growth in the US market for general and pelvic endoscopes (including rigid and flexible endoscopes and equipment) is projected to increase from $803.9 million in 2013 to more than $1 billion in 2018, a CAGR of 4.9% according to a recent Medtech Insight market report. (See Exhibit 1.) Companies competing in this market include Olympus Medical Systems Group (Center Valley, PA), a division of Olympus Corp.), Stryker Corp

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Asia

Medical Devices Not The Focus Of FDA’s Plans To Step Up Foreign Inspections, Expert Says

 

The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.

Consumer Healthtech Investment Totaled $4.5BN In 2024, But Bar Is High Amid Economic Uncertainty

 
• By 

Global investment in consumer healthtech increased by 9% year-over-year in 2024, totaling $4.5bn, with significant interest in mental health solutions, according to Galen Growth. While the first quarter of 2025 saw raised confidence and investments, the Trump administration’s new tariffs and sweeping changes to healthcare have introduced new uncertainties.

Don’t Sleep On Inspections: Experts Warn FDA Maintains Enforcement Resources

 

Manufacturers of medical products would be foolish to think that recent upheavals at the US FDA will result in a lack of inspections in the coming years. A panel of experts discussed the current state of inspections during a webinar hosted by the Food and Drug Law Institute.

South Korea Adds Digital Health Rules To Already Complicated Regulatory Landscape

 
• By 

A New South Korean law, the Digital Medical Products Act, enhances regulation for digital health products. Medical devices in the country are categorized both by risk and by similarity to already authorized devices. The approval process may stretch to 515 days for new manufacturers.

More from Geography

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.